Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects

Chronic HBV Infection Clinical Trial

Official title:

Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of Single and Multiple Administration of Oral PA3670 Tablets in Chinese Healthy Subjects and the Effect of Food on Pharmacokinetics

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05851261
• Other study ID #: PA3670-101
• Status: Completed
• Phase: Phase 1
• Start date: April 13, 2023
• Est. completion date: December 19, 2023

Study information

• Verified date: April 2024
• Source: Zhejiang Palo Alto Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objectives of this study are to evaluate the safety and tolerance of single and multiple oral administration of PA3670 tablets in Chinese adult healthy subjects and the effect of food on pharmacokinetics of PA3670 tablets in Chinese adult healthy subjects.

Description:

Stage I: Single dose, Single Ascending Dose (SAD) This is a randomized, double-blind, placebo-controlled, dose-escalation clinical trial. The objective is to evaluate the safety, tolerability and pharmacokinetics characteristics of PA3670 tablets in Chinese healthy subjects. There are three dose groups of PA3670(5 mg、15 mg、30 mg) proposed to be tested sequentially in this study. A total of 30 healthy subjects are planned to be enrolled in this study and will be randomly assigned to the corresponding dose group in equal proportion, stratified by gender (male vs female). 10 subjects in each dose group are randomly assigned in a ratio of 4:1 to receive PA3670 tablets or placebo. All subjects will be dosed in a single dose, and the dose-related safety, tolerability and PK of PA3670 will be evaluated. Stage Ⅱ: Multiple dose This is a randomized, double-blind, placebo-controlled, multiple dose clinical trial. A total of 10 subjects are planned to be enrolled in this study and will be randomly assigned in a ratio of 4:1 to receive 15mg PA3670 tablets or placebo. All subjects will be dosed for 9 consecutive days, and safety, tolerability and PK of PA3670 will be evaluated. Stage Ⅲ: Study on the effect of food on Pharmacokinetics This is a randomized, open, two group crossover clinical trial. A total of 20 subjects are planned to be enrolled in this study, and will be randomly assigned to a dosing order (i.e. fasting administration followed by high-fat meal administration, or high-fat meal administration followed by fasting administration) in a ratio of 1:1. Subjects will be dosed 15 mg PA3670 tablets in a single dose, and the food-related PK of PA1010 will be evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 19, 2023
• Est. primary completion date: October 24, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• 1. Healthy male and female subjects aged from 18 to 65 (inclusive);
• 2. Male weight = 50 kg, female weight = 45 kg, and body mass index (BMI) between 19 and 28 kg/m2 (including the critical value);
• 3. Be able to complete the test according to the study protocol;
• 4. Voluntary participation and signing of informed consent.

Exclusion Criteria:

• 1. There are any medical conditions that the investigator thinks may increase the risk of the subject participating in the study (especially the history of esophageal or gastrointestinal ulcer), may interfere with drug absorption, distribution, metabolism or excretion, or may weaken the compliance of the study protocol;
• 2. Allergic to the study drug or any component of the study drug, or allergic (refers to allergic to 2 or more kinds of food, drugs or environmental substances);
• 3. The vital signs, physical examination, laboratory examination (blood routine test, blood biochemistry, urine routine test, blood coagulation function, etc.), chest X-ray examination, abdominal B-ultrasound (liver, gallbladder, pancreas, spleen, kidney), 12 lead ECG, etc. in the screening period were judged abnormal and had clinical significance;
• 4. Those who are positive for hepatitis B surface antigen, hepatitis C virus antibody, treponema pallidum antibody and HIV antibody;
• 5. Those who regularly drank alcohol within 3 months before screening, i.e., those who drank more than 14 units of alcohol every week (1 unit=360 mL of beer with 5% alcohol content, 45 mL of spirits with 40% alcohol content, or 150 mL of wine with 12% alcohol content), or those who had positive alcohol breath test in the baseline period or could not stop drinking alcohol during the study period;
• 6. Those who smoke = 5 cigarettes a day within 3 months before screening, those who are positive for nicotine test in the baseline period, or those who cannot stop using any tobacco products during the test period;
• 7. Those who have a history of drug abuse and drug abuse in the past two years, or who are positive for urine screening of drug abuse at baseline (including morphine, methamphetamine, ketamine, benzodiazepine, cocaine, tetrahydrocannabinol acid);
• 8. Those who have used any drugs (prescription drugs, over-the-counter drugs, Chinese herbal medicine, vaccines) or health products within 4 weeks before screening and during screening;
• 9. Those who take any food or drink rich in caffeine and xanthine (coffee, tea, cola, chocolate, seafood, animal liver, etc.) within 48 hours before the first use of the study drug, or do not agree to stop eating the above diet during the test period;
• 10. Female subjects had unprotected sex in the past two weeks; Male subjects (or their partners) or female subjects who have fertility plans or donated sperm and eggs during the whole test period and within 3 months after administration, and who are unwilling to take one or more physical contraceptive measures or are breastfeeding during the test period;
• 11. Those who donate blood or lose a lot of blood (= 200 mL, except female physiological period) or use blood products or transfusions within 90 days before screening and during screening;
• 12. Those who participated in other clinical study within 90 days before screening or who participated in other clinical trials for less than 7 days;
• 13. Those who have undergone major surgery within 6 months before screening (judged by the researcher based on previous medical history data), suffered major trauma or planned to undergo surgery during the study period;
• 14. Difficulty in venous blood collection, or known history of needle and blood fainting;
• 15. Positive blood pregnancy test during screening period;
• 16. The investigator considers that there are other circumstances that are not suitable for participating in the test.

Related Conditions & MeSH terms

• Chronic HBV Infection

Intervention

Drug:
• PA3670
Placebo as control

Locations

Country	Name	City	State
China	The Second Affiliated Hospital of Chongqing Medical University	Chongqing	Chongqing

Sponsors (1)

Lead Sponsor	Collaborator
Zhejiang Palo Alto Pharmaceuticals, Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Body temperature	Vital sign-body temperature	Up to 72 hours after last dose
Primary	Systolic and diastolic blood pressure	Vital sign-Systolic and diastolic blood pressure	Up to 72 hours after last dose
Primary	Pulse rate	Vital sign-Pulse rate	Up to 72 hours after last dose
Primary	Breathing rate	Vital sign-Breathing rate	Up to 72 hours after last dose
Primary	Number of subjects having abnormal hematology laboratory parameters	Absolute and relative number of subjects with values below, within or above the normal range will be assessed.	Up to 72 hours after last dose
Primary	Number of subjects with abnormal clinical chemistry parameters	Absolute and relative number of subjects with values below, within or above the normal range will be assessed.	Up to 72 hours after last dose
Primary	Number of subjects with abnormal values for urinalysis	Absolute and relative number of subjects with values below, within or above the normal range will be assessed.	Up to 72 hours after last dose
Primary	Number of subjects with abnormal with blood coagulation function	Absolute and relative number of subjects with values below, within or above the normal range will be assessed.	Up to 72 hours after last dose
Primary	ECG parameter-QTc interval	A 12-lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures QTc interval	Up to 72 hours after last dose
Primary	ECG parameter-PR interval	A 12-lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures PR interval.	Up to 72 hours after last dose
Primary	ECG parameter-QRS duration	A 12-lead electrocardiogram (ECG) will be recorded using an ECG machine that automatically measures QRS duration	Up to 72 hours after last dose
Primary	Number of subjects experiencing adverse events (AEs)	An adverse event (AE) is defined as any untoward medical occurrence in a clinical study subject administered a medicinal product which does not necessarily have a causal relationship with this treatment.	7 days or 15 days
Secondary	Pharmacokinetics of PA3670-Cmax	Blood samples will be collected serially, and the concentrations of PA3670 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Maximum Observed Plasma Concentration (Cmax)	4 days or 12 days
Secondary	Pharmacokinetics of PA3670-Tmax	Blood samples will be collected serially, and the concentrations of PA3670 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Time to Reach Maximum Observed Plasma Concentration (Tmax)	4 days or 12 days
Secondary	Pharmacokinetics of single dose of PA3670-AUC	Blood samples will be collected serially, and the concentrations of PA3670 in plasma samples are determined by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS), followed by the calculation of pharmacokinetic parameter Area Under the Plasma Concentration-Time Curve (AUC)	4 days or 12 days